Vomiting News and Research

RSS
Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.
Acacia Pharma reports positive results from APD403 Phase 2 study in CINV

Acacia Pharma reports positive results from APD403 Phase 2 study in CINV

IQWiG finds minor added benefit of dulaglutide in combination with short-acting insulin for type 2 diabetes

IQWiG finds minor added benefit of dulaglutide in combination with short-acting insulin for type 2 diabetes

Researchers reveal potential mode of drug resistance in malaria parasites

Researchers reveal potential mode of drug resistance in malaria parasites

Plastic surgeons find association between carpal tunnel syndrome and migraine headache

Plastic surgeons find association between carpal tunnel syndrome and migraine headache

Actavis reports positive results from phase 3 study of single-dose DALVANCE for treatment of ABSSSI

Actavis reports positive results from phase 3 study of single-dose DALVANCE for treatment of ABSSSI

NUH develops new treatment guidelines to support women suffering from Hyperemesis

NUH develops new treatment guidelines to support women suffering from Hyperemesis

Study: Combination therapy shows high SVR rates in HCV patients with decompensated liver disease

Study: Combination therapy shows high SVR rates in HCV patients with decompensated liver disease

Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Acacia Pharma begins APD421 Phase 3 study in combination with standard anti-emetics for PONV

Acacia Pharma begins APD421 Phase 3 study in combination with standard anti-emetics for PONV

Extreme morning sickness during pregnancy linked to developmental problems in children

Extreme morning sickness during pregnancy linked to developmental problems in children

Experimental immune therapy generally safe, well-tolerated in women with triple-negative breast cancer

Experimental immune therapy generally safe, well-tolerated in women with triple-negative breast cancer

New OCT angiography can improve clinical management of leading causes of blindness

New OCT angiography can improve clinical management of leading causes of blindness

Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients

Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Rhythm, Actavis announce initiation of relamorelin Phase 2b trial for treatment of diabetic gastroparesis

Rhythm, Actavis announce initiation of relamorelin Phase 2b trial for treatment of diabetic gastroparesis

New study analyses physical, psychological consequences of bariatric surgery

New study analyses physical, psychological consequences of bariatric surgery

Study examines new Ebola Prediction Score

Study examines new Ebola Prediction Score

Rhode Island Hospital physician comes up with new diagnostic tool for Ebola virus

Rhode Island Hospital physician comes up with new diagnostic tool for Ebola virus

Shire announces availability of Natpara (parathyroid hormone) for injection in U.S.

Shire announces availability of Natpara (parathyroid hormone) for injection in U.S.

MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.